Edgewise Therapeutics Stock Investor Sentiment
| EWTX Stock | USD 25.57 0.49 1.95% |
Slightly above 61% of all Edgewise Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Edgewise Therapeutics suggests that some traders are interested. Edgewise Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Edgewise Therapeutics' earnings reports, geopolitical events, and overall market trends.
Comfort Level 61
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Edgewise Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Edgewise Therapeutics.
News SentimentBullish | Hype SentimentBullish | Insider SentimentDisposing |
Edgewise Historical Sentiment
Although Edgewise Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Edgewise, such as negative comments on social media and news outlets, may cause fear in the market and push Edgewise Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Edgewise.
Edgewise |
Edgewise Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Edgewise Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Edgewise Therapeutics Historical Investor Sentiment
Investor biases related to Edgewise Therapeutics' public news can be used to forecast risks associated with an investment in Edgewise. The trend in average sentiment can be used to explain how an investor holding Edgewise can time the market purely based on public headlines and social activities around Edgewise Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Edgewise Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Edgewise Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Edgewise Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Edgewise Therapeutics.
Far too much social signal, news, headlines, and media speculation about Edgewise Therapeutics that are available to investors today. That information is available publicly through Edgewise media outlets and privately through word of mouth or via Edgewise internal channels. However, regardless of the origin, that massive amount of Edgewise data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Edgewise Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Edgewise Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Edgewise Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Edgewise Therapeutics alpha.
Edgewise Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Edgewise Therapeutics shares target lifted, buy rating on positive outlook | 11/27/2024 |
2 | EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study | 12/17/2024 |
3 | Disposition of 1729 shares by Semigran Marc of Edgewise Therapeutics at 30.0803 subject to Rule 16b-3 | 12/24/2024 |
4 | Disposition of 100000 shares by Alan Russell of Edgewise Therapeutics at 27.3747 subject to Rule 16b-3 | 12/30/2024 |
5 | Disposition of 24960 shares by Carruthers R Michael of Edgewise Therapeutics at 28.5862 subject to Rule 16b-3 | 01/03/2025 |
6 | Insider Trading | 01/21/2025 |
7 | Edgewise Therapeutics Strengthens Leadership Team, Appoints Merck Veteran as Chief Development Officer - StockTitan | 01/22/2025 |
8 | Why Is Andreas Halvorsen Bullish On Edgewise Therapeutics, Inc. Now | 01/23/2025 |
9 | Disposition of 25000 shares by Donovan Joanne M. of Edgewise Therapeutics at 27.6263 subject to Rule 16b-3 | 01/28/2025 |
10 | Moody Aldrich Partners LLC Increases Stock Position in Edgewise Therapeutics, Inc. - MarketBeat | 01/29/2025 |
11 | Disposition of 10000 shares by Behrad Derakhshan of Edgewise Therapeutics at 30.03 subject to Rule 16b-3 | 02/05/2025 |
12 | Disposition of 900 shares by Kevin Koch of Edgewise Therapeutics at 31.1311 subject to Rule 16b-3 | 02/06/2025 |
13 | abrdn plc Has 4.75 Million Stake in Edgewise Therapeutics, Inc. - MarketBeat | 02/13/2025 |
Additional Tools for Edgewise Stock Analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.